



## **ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021**

September 7, 2021

**ZYVERSA IS WELL POSITIONED IN THE RAPIDLY EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC INHIBITOR, IC 100, WHICH HAS POTENTIAL TO TREAT A BROAD RANGE OF INFLAMMATORY DISEASES**

**ZYVERSA'S PIPELINE INCLUDES VAR 200, A PHASE 2A-READY FIRST-IN-CLASS CHOLESTEROL EFFLUX MEDIATOR FOR TREATMENT OF ORPHAN RENAL DISEASE, FSGS, AND OTHER GLOMERULAR CONDITIONS**

WESTON, Fla., Sept. 7, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. For conference details, [Click Here](#).



To learn more about ZyVersa and its novel inflammasome inhibitor IC 100, please schedule a 1 on 1 virtual meeting.

Mr. Glover's presentation will highlight progress in advancing development of ZyVersa's inflammasome ASC inhibitor IC 100, and Phase 2a-ready VAR 200 for orphan renal disease, FSGS.

Mr. Glover's presentation will be available to registered conference attendees for on-demand viewing beginning **Monday, September 13, 2021, at 7:00 AM Eastern**.


To learn more about ZyVersa and its novel inflammasome inhibitor IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease, please schedule a 1 on 1 virtual meeting with ZyVersa using the conference portal.

### **About ZyVersa Therapeutics, Inc.**

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome ASC inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS) and other glomerular conditions. For more information, please

visit [www.zyversa.com](http://www.zyversa.com).



 View original content to download multimedia:<https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephen-c-glover-invited-speaker-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-2021-301369194.html>

SOURCE ZyVersa Therapeutics, Inc.